Cholestyramine nonclinical toxicology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cholestyramine}} {{CMG}}; {{AE}} {{SS}} ==Nonclinical Toxicology== In studies conducted in rats in which cholestyramine resin was used as a tool to investigate ...")
 
(Redirected page to Cholestyramine)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Cholestyramine]]
{{Cholestyramine}}
{{CMG}}; {{AE}} {{SS}}
 
==Nonclinical Toxicology==
 
 
In studies conducted in rats in which cholestyramine resin was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin-treated rats than in control rats.
 
The relevance of this laboratory observation from studies in rats to the clinical use of cholestyramine resin is not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal neoplasms was similar in both treatment groups. When the many different categories of tumors are examined, various alimentary system cancers were somewhat more prevalent in the cholestyramine group. The small numbers and the multiple categories prevent conclusions from being drawn. However, in view of the fact that cholestyramine resin is confined to the GI tract and not absorbed, and in light of the animal experiments referred to above, a six-year post-trial follow-up of the LRC-CPPT5 patient population has been completed (a total of 13.4 years of in-trial plus post-trial follow-up) and revealed no significant difference in the incidence of cause-specific mortality or cancer morbidity between cholestyramine and placebo treated patients.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PREVALITE (CHOLESTYRAMINE) POWDER, FOR SUSPENSION [UPSHER-SMITH LABORATORIES INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd434ef8-8af3-434c-a0a0-9a0b18459ba0 | publisher =  | date =  | accessdate = 10 February 2014 }}</ref>
 
 
==References==
 
{{Reflist|2}}
 
{{Lipid modifying agents}}
 
[[Category:Hepatology]]
[[Category:Bile acid sequestrants]]
[[Category:Cardiovasuclar Drugs]]
[[Category:Drugs]]

Latest revision as of 13:53, 21 July 2014

Redirect to: